Symptoms of COVID-19 among older adults: systematic review of biomedical literature

Sacco, Guillaume; Brière, Olivier; Asfar, Marine; Guérin, Olivier; Berrut, Gilles; Annweiler, Cédric

doi:10.1684/pnv.2020.0863

Cited by 16 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This case series showed that frail older adults exhibit relatively few symptoms, and notably less often fever, cough [11] and ENT signs [12] than younger adults. In this sense, our results are consistent with the few previous studies on symptoms met in older adults infected with COVID-19 [2,3]. It is also consistent with the clinical presentation of other viral infections in older adults such as influenza [13].…”

Section: Discussionsupporting

confidence: 92%

“…First epidemiological data confirm that older adults are more prone to develop severe and lethal forms of COVID-19 [1]. Clinical data regarding older patients' symptomatology are yet limited [2], and the first report on oldest-old people (i.e., aged 80 years and over) with major neurocognitive disorders revealed clinical peculiarities that make difficult to diagnose COVID-19 during the first days of the infection [3]. What is more, previous studies described individuals for whom tests had been performed following a clinical suspicion, which could have biased the prevalence of some symptoms [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 in seniors: Findings and lessons from mass screening in a nursing home

Sacco

Foucault²,

Brière³

et al. 2020

Maturitas

Self Cite

View full text Add to dashboard Cite

Background/objective: The COVID-19 epidemic is particularly serious in older adults. The symptomatology and epidemic profile remain little known in this population, especially in disabled oldest-old people with chronic diseases living in nursing homes. The objective of the present study was to comprehensively describe symptoms and chronological aspects of the diffusion of the SARS-CoV-2 virus in a nursing home, among both residents and caregivers. Design: Five-week retrospective cohort study. Setting: A middle-sized nursing home in Maine-et-Loire, west of France. Participants: Eighty-seven frail older residents (87.9 ± 7.2years; 71 % female) and 92 staff members (38.3 ± 11.7years; 89 % female) were included. Measurements: Mass screening for SARS-CoV-2 was performed in both residents and staff. Attack rate, mortality rate, and symptoms among residents and staff infected with SARS-CoV-2 were recorded. Results: The attack rate of COVID-19 was 47 % in residents (case fatality rate, 27 %), and 24 % in staff. Epidemic curves revealed that the epidemic started in residents before spreading to caregivers. Residents exhibited both general and respiratory signs (59 % hyperthermia, 49 % cough, 42 % polypnea) together with geriatric syndromes (15 % falls, 10 % altered consciousness). The classification tree revealed 100 % COVID-19 probability in the following groups: i) residents younger than 90 with dyspnea and falls; ii) residents older than 90 with anorexia; iii) residents older than 90 without anorexia but with altered consciousness. Finally, 41 % of staff members diagnosed with COVID-19 were asymptomatic. Conclusions: The pauci-symptomatic expression of COVID-19 in older residents, together with the high prevalence of asymptomatic forms in caregivers, justifies mass screening in nursing homes, possibly prioritizing residents with suggestive combinations of clinical signs including dyspnea, falls, anorexia and/or altered consciousness.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

COVID-19 in seniors: Findings and lessons from mass screening in a nursing home

Sacco

Foucault²,

Brière³

et al. 2020

Maturitas

Self Cite

View full text Add to dashboard Cite

show abstract

“…As of June 4, 2020, the COVID-19 pandemic caused by the SARS-CoV-2 virus has seen the infection of more than 6,300,000 people in 194 countries around the world, leaving more than 380,000 dead [ 1 ]. Symptoms include fever, marked asthenia and dry cough, which may gradually progress to severe manifestations such as lethal acute respiratory disease syndrome (ARDS) [ 2 ]. With the lack of scientifically-validated treatment, chemoprevention and vaccination, the immediate repurposing of existing drugs gives hope of curbing the pandemic.…”

Section: Introductionmentioning

confidence: 99%

Point of view: Should COVID-19 patients be supplemented with vitamin D?

2020

Self Cite

View full text Add to dashboard Cite

Highlights Vitamin D may mitigate COVID-19 through its effects on gene expression. Increased vitamin D concentration is associated with better prognosis in COVID-19 cases. The benefits of vitamin D supplementation in COVID-19 patients remain to be determined. The use of vitamin D supplements as an adjuvant treatment for COVID-19 needs to be examined urgently.

show abstract

“…Although a significant number of individuals infected with the SARS-CoV-2 remain asymptomatic and unrecognized, infected patients typically develop pneumonia which may lead to severe complications such as acute respiratory distress syndrome and multiple organ failure. So far, significant number of adults and children were affected from this disease and pandemic continues to spread widely and rapidly across the world ( Rathore et al, 2020 ; Sacco et al, 2020 ). As of October 27, 2020, a total of 43,561,060 confirmed cases of COVID-19 and 1,160,389 deaths have been reported globally ( https://coronavirus.jhu.edu/map.html ).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic potential of miRNAs targeting SARS-CoV-2 host cell receptor ACE2

Bozgeyik

2021

Meta Gene

View full text Add to dashboard Cite

In late December 2019, several cases of pneumonia of unknown etiology (COVID-19) were reported in Wuhan, Hubei province, China. Based on clinical findings, blood tests and chest radiographs, this disease was diagnosed as a virus-associated pneumonia. Sequence analysis revealed a novel coronavirus, called SARS-CoV-2 (formerly called 2019-nCoV), as the causative agent of pneumonia of unknown etiology. So far, the SARS-CoV-2 infection continues to spread, and this virus poses a serious public health threat. In this study, it was aimed to reveal potential miRNA targets for the regulation of SARS-CoV-2 host cell receptor ACE2. For the identification of potential miRNA targets for the ACE2 gene, TarBase v.8 (DIANA Tools), TargetScan, miRTarBase and miRDB miRNA-target prediction algorithms were used. FANTOM5 CAGE was used for the cellular ontology analysis. Expression levels of these miRNAs were determined using OncomiR Pan-Cancer miRNome Atlas. The results suggest that members of miR-200 family of miRNAs, especially miR-200c-3p, are strong candidate targets for the regulation of ACE2 in respiratory system cells. Consequently, the present study for the first time emphasizes potential use of miRNA-based therapeutics in the battle against SARS-CoV-2 infection and its deadly disease, COVID-19.

show abstract

Symptoms of COVID-19 among older adults: systematic review of biomedical literature

Cited by 16 publications

References 0 publications

COVID-19 in seniors: Findings and lessons from mass screening in a nursing home

COVID-19 in seniors: Findings and lessons from mass screening in a nursing home

Point of view: Should COVID-19 patients be supplemented with vitamin D?

Therapeutic potential of miRNAs targeting SARS-CoV-2 host cell receptor ACE2

Contact Info

Product

Resources

About